Animal model

Every year, 10 million people contract tuberculosis (TB), a disease caused by the bacterium Mycobacterium tuberculosis (Mtb), and approximately 1.5 million patients succumb to the disease. Treatment

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)

Two DZIF junior scientists—Prof Philipp Schommers and Dr Alexander Simonis—have been honoured with silver medals by the Walter Siegenthaler Society for their fundamental medical research in the field

Antibacterial drugs are important for treating infections. However, increasing bacterial resistance to current drugs—making them ineffective or only partially effective—means that new drugs are

The protective effect of established COVID-19 vaccines is initially very robust, but wanes relatively quickly. This limitation imposes a need for periodic booster shots, which drives vaccine

Darobactin is a promising candidate for the development of new, resistance-breaking antibiotics, as it has an exceptional mechanism of action and a broad spectrum of activity. In a recent study, DZIF

The Faculty of Medicine at the University of Basel has awarded an honorary doctorate to DZIF Professor Dr Stephan Urban from the Medical Faculty at the Heidelberg University. The award acknowledges

Antibiotic-resistant bacteria pose a major challenge to healthcare systems worldwide. Due to numerous resistance mechanisms, infections with the pathogen Pseudomonas aeruginosa are particularly feared